Madoz-Gúrpide J, Zazo S, Chamizo C, Casado V, Caramés C, Gavín E, Cristóbal I, García-Foncillas J, Rojo F. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. Journal of Translational Medicine. 2015 Aug 29;13(1):282. doi: 10.1186/s12967-015-0633-7.